BioSpace News Archive

OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, Ph.D., President and CEO, will speak to the investment community at the Jefferies 2020 Healthcare Conference.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 11:00 am ET.

Emgality® significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month double-blind period of the CONQUER study, which included patients with migraine from 12 different countries.

- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial - - Top Line Results of Pivotal CONNECT-FX Trial Expected Late in the Second Quarter of 2020 -

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:30 AM ET.

Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby reduce mortality and the need for ventilation

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced the filing of a New Drug Submission with Health Canada for Triferic AVNU.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that management will host investor conference calls through June

BioCryst Pharmaceuticals, Inc. announced that the company will present new data on berotralstat, an oral, once-daily therapy under regulatory review in the United States, Japan and the European Union for the prevention of hereditary angioedema attacks, at the upcoming digital congress of the European Academy of Allergy and Clinical Immunology June 6-8.

Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced the publication of an electronic-poster with clinical data from the Company’s AWARE-1 window-of-opportunity breast cancer study.